ROSEN, TRUSTED INVESTOR ADVISOR, encourages investors of Applied Therapeutics, Inc. to provide counsel before an important deadline in a securities class action

New York, New York–(Newsfile Corp. – December 29, 2024) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: NASDAQ: ) between January 3, 2024 and December 2, 2024, both dates inclusive (the “Class Period”), to the extent February 18, 2025, deadline for the chief prosecutor.

SO WHAT: If you purchased securities of Applied Therapeutics during the Lecture Period, you may be entitled to compensation without paying any fees or out-of-pocket expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Applied Therapeutics class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=32500 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than February 18, 2025. The lead plaintiff is the representative party that acts on behalf of the other class members in the conduct of the litigation.

WHY ROSEN’S LAW: We encourage investors to choose a qualified advisor with experience in successful leadership roles. Often the firms issuing the notices do not have comparable experience, resources or any significant recognition from their peers. Many of these firms do not actually initiate securities class action lawsuits, but are merely brokers who refer clients or are partners with the law firms that actually initiate the cases. Be wise in choosing an advisor. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and equity derivative litigation. The Rosen Law Firm secured the largest securities class action settlement to date against a Chinese company at the time. The Rosen Law Firm is ranked #1 by ISS Securities Class Action (WA:) Services for numerous securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named a Law360 Claimant Bar Association Titan. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the statements made during the lecture were false and/or materially misleading because they concealed and misrepresented the clinical trial protocols and procedures Applied Therapeutics had in place. Therefore, the defendants gave investors the false impression that protocol and good clinical practice were being followed correctly. The lawsuit alleges that, in fact, Applied Therapeutics failed to adhere to the trial protocol and good clinical practice, which in turn created an extremely serious risk that the trial data would be rejected by the US Food and Drug Administration (“FDA”) in the context of applying the new medicine. When the true details came to market, the lawsuit alleges, investors suffered damages.

To join the Applied Therapeutics class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=32500 call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.

No class is certified. Until the class is certified, you will not be represented by an attorney unless you retain one. You can choose a lawyer of your choice. You can also remain an absent member of the class and do nothing at this time. An investor’s ability to participate in a potential future recovery does not depend on whether it is the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm.

Advertising of lawyers. Previous results do not guarantee a similar outcome.

——————————–

To view the original version of this press release, visit https://www.newsfilecorp.com/release/235115